Patient-friendly peptide education
General peptide therapy, clinics, safety, brands and long-tail topics.
Recently published
Peptide Cancer Risk Personal Research Exploration Tips via Peptide Cancer Risk Evolving consumer cognition reshapes how bioactive peptide raw materials are evaluated within modern technical market environments…
Read guide →Dive Brief: An experimental therapy from Allogene helped eliminate signs of cancer better than standard treatment in a Phase 3 trial in first-line large B-cell lymphoma, results suggesting the biotechnology co…
Read guide →Dive Brief: Avalyn Pharma on Wednesday raised $300 million in a large initial public offering that’ll support development of a portfolio of drugs for hard-to-treat lung diseases. The Boston biotechnology compa…
Read guide →Today, a brief rundown of news from Replimune and MeiraGTx, as well as updates from Revolution Medicines and Biogen that you may have missed. Replimune is turning to layoffs following its second drug rejection…
Read guide →Biotechnology startup Latus Bio has secured new venture funding to bring into clinical testing a different kind of gene therapy for Huntingtion’s disease, the progressive neurodegenerative condition. Latus on …
Read guide →Bcl Xl Beclin 1 Peptide Complex Pdb How Bcl Xl Beclin 1 Peptide Complex Pdb Improves Basic Formula Environmental Adaptability Customization of peptide sequences has become more accessible as automated synthesi…
Read guide →Blood disease specialist Hemab Therapeutics and brain drug developer Seaport Therapeutics both priced initial public offerings on Thursday evening, hauling in a combined $556.4 million to fund the advancement …
Read guide →With quarterly earnings underway, BioPharma Dive is providing a snapshot of some companies’ results and how they’re being received by investors. Today, we’re offering insight into the latest numbers from Brist…
Read guide →Viridian Therapeutics said Tuesday its injectable drug for thyroid eye disease scored in a second late-stage trial, strengthening its position as a competitive threat to Amgen’s blockbuster therapy Tepezza. Vi…
Read guide →Peptide Fürs Gehirn Peptide Fürs Gehirn: Iterative Formulation Testing From My Laboratory Work Market demand for peptide materials has shifted toward more specialized and functionally distinct product categori…
Read guide →Dive Brief: An experimental cancer immunotherapy from Regeneron failed a late-stage study in melanoma in a surprise setback for the big biotechnology company’s oncology business. A regimen involving the prospe…
Read guide →Peptide Protocols By William A Seeds Pdf Examining The Signal Regulation Of Peptide Protocols By William A Seeds Pdf:Molecular Interaction Logic The perception of peptide molecules as advanced bioactive agents…
Read guide →Dive Brief: A drug prospect from Relay Therapeutics has shown signs in a mid-stage clinical trial that it may be able to treat a cluster of conditions associated with the development of abnormal blood vessels.…
Read guide →Today, a brief rundown of news involving Astellas Pharma and Moderna, as well as updates from AstraZeneca, Daiichi Sankyo and Gilead Sciences that you may have missed. Astellas Pharma is planning new cost cuts…
Read guide →Today, a brief rundown of news involving Allogene and Agios Pharmaceuticals, as well as updates from AbbVie, AstraZeneca and BridgeBio Pharma that you may have missed. Allogene CEO David Chang will step aside …
Read guide →ADC Therapeutics said its blood cancer drug met the main goal of a confirmatory trial, but the experiment recorded more deaths among patients treated with the drug, sending shares down more than 50% Thursday m…
Read guide →Today, a brief rundown of news involving NewLimit and Eli Lilly, as well as updates from Praxis Precision Medicines and Regeneron Pharmaceuticals that you may have missed. Longevity startup NewLimit has raised…
Read guide →Purchase Peptides The Practical Research Advantages Of Purchase Peptides In Laboratory Tests Breakthroughs in peptide stabilization technologies have expanded the practical applications of these molecular inte…
Read guide →City Therapeutics, a young biotechnology firm working on new RNA interference therapies, has banked $99.5 million to fund further testing of its medicines, the company said Tuesday. Dubbed “CITY-FXI,” City’s l…
Read guide →An emerging area of drug development got more crowded Wednesday, with the debut of a biotechnology startup trying to create new migraine prevention therapies. Vedana Therapeutics formed in response to an earli…
Read guide →Browse by subject
Each topic opens a crawlable collection of related articles and resources.